MX2020011909A - Uso de canakinumab. - Google Patents

Uso de canakinumab.

Info

Publication number
MX2020011909A
MX2020011909A MX2020011909A MX2020011909A MX2020011909A MX 2020011909 A MX2020011909 A MX 2020011909A MX 2020011909 A MX2020011909 A MX 2020011909A MX 2020011909 A MX2020011909 A MX 2020011909A MX 2020011909 A MX2020011909 A MX 2020011909A
Authority
MX
Mexico
Prior art keywords
canakinumab
osteoarthritis
inhibitor
prevention
treatment
Prior art date
Application number
MX2020011909A
Other languages
English (en)
Spanish (es)
Inventor
Mattias Schieker
Linda Mindeholm
Jens Praestgaard
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020011909A publication Critical patent/MX2020011909A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2020011909A 2018-05-09 2018-08-24 Uso de canakinumab. MX2020011909A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862669071P 2018-05-09 2018-05-09
PCT/IB2018/056455 WO2019215484A1 (en) 2018-05-09 2018-08-24 Use of canakinumab

Publications (1)

Publication Number Publication Date
MX2020011909A true MX2020011909A (es) 2021-01-29

Family

ID=63638190

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011909A MX2020011909A (es) 2018-05-09 2018-08-24 Uso de canakinumab.

Country Status (12)

Country Link
US (1) US20210371511A1 (enExample)
EP (1) EP3790576A1 (enExample)
JP (2) JP2021523894A (enExample)
KR (1) KR20210008847A (enExample)
CN (2) CN119746057A (enExample)
AU (1) AU2018422406A1 (enExample)
BR (1) BR112020022576A2 (enExample)
CA (1) CA3098277A1 (enExample)
CL (1) CL2020002881A1 (enExample)
MX (1) MX2020011909A (enExample)
TW (1) TW201946652A (enExample)
WO (1) WO2019215484A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
PL2848258T3 (pl) 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
HRP20251174T1 (hr) * 2010-11-05 2025-11-21 Novartis Ag Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista
BR112014007253A2 (pt) * 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
US20150203592A1 (en) * 2013-12-02 2015-07-23 Abbvie Inc. Compositions and methods for treating osteoarthritis
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
AU2018287519B2 (en) * 2017-06-22 2021-07-22 Novartis Ag IL-1beta binding antibodies for use in treating cancer
CN107723310B (zh) * 2017-10-19 2024-01-09 北京睿诚海汇健康科技有限公司 植物作为宿主在表达卡那抗体中的应用

Also Published As

Publication number Publication date
BR112020022576A2 (pt) 2021-02-09
TW201946652A (zh) 2019-12-16
KR20210008847A (ko) 2021-01-25
AU2018422406A1 (en) 2020-11-12
CL2020002881A1 (es) 2021-05-14
JP2023071904A (ja) 2023-05-23
CA3098277A1 (en) 2019-11-14
WO2019215484A1 (en) 2019-11-14
EP3790576A1 (en) 2021-03-17
US20210371511A1 (en) 2021-12-02
JP2021523894A (ja) 2021-09-09
JP7713983B2 (ja) 2025-07-28
CN119746057A (zh) 2025-04-04
CN112584857A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
EP4234551A3 (en) Pyridazinones as parp7 inhibitors
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
WO2020252229A3 (en) Inhibitors of sarm1
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX2023013912A (es) Metodos para inhibir ras.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2022015753A (es) Metodos y composiciones para tratamiento de epidermolisis ampollosa.
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
PH12019502915A1 (en) Immunogenic compositions
MY209468A (en) Masp-2 inhibitors and methods of use
EP4438124A3 (en) Methods for treating testicular and ovarian adrenal rest tumors
EP3775263A4 (en) COMPOSITIONS AND METHODS OF TREATING ACNE
ZA202200775B (en) Compositions for the treatment of hair loss
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
ZA202211980B (en) Methods and treatment of trauma
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
ZA202000354B (en) Novel braf inhibitors and use thereof for treatment of cutaneous reactions
MX2021004387A (es) Composiciones y metodos para el tratamiento de sindrome vascular de ehlers danlos y trastornos asociados.
ZA202200266B (en) Composition for prostaglandin transporter inhibition and related therapeutic applications
AU2020378127A8 (en) Compounds as CD73 inhibitors
PH12021552499A1 (en) Methods for the treatment of beta-thalassemia
MX2021001877A (es) Composiciones y métodos para el tratamiento de lesión pulmonar aguda.
MX2020011909A (es) Uso de canakinumab.